Anshul Maheshwari Sells 1,733 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari sold 1,733 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $17.59, for a total value of $30,483.47. Following the sale, the chief financial officer now directly owns 148,738 shares in the company, valued at $2,616,301.42. The sale was disclosed in a filing with the SEC, which is available through this link.

Anshul Maheshwari also recently made the following trade(s):

• On Monday, October 2nd, Anshul Maheshwari sold 1,244 shares of SI-BONE stock. The stock was sold at an average price of $21.15, for a total value of $26,310.60.

SI-BONE Stock Up 2.9 %

Shares of SIBN traded up $0.50 during midday trading on Monday, reaching $18.04. 230,933 shares of the stock were exchanged, compared to its average volume of 355,422. SI-BONE, Inc. has a 52 week low of $11.14 and a 52 week high of $29.51. The company has a current ratio of 10.89, a quick ratio of 9.74 and a debt-to-equity ratio of 0.21. The company’s 50 day moving average is $18.93 and its two-hundred day moving average is $22.72. The company has a market capitalization of $730.64 million, a P/E ratio of -15.16 and a beta of 0.99.

Institutional Investors Weigh In On SI-BONE

Institutional investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its position in SI-BONE by 28.7% during the first quarter. FMR LLC now owns 2,160 shares of the company’s stock valued at $42,000 after purchasing an additional 482 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new stake in SI-BONE in the second quarter valued at about $47,000. Ensign Peak Advisors Inc purchased a new stake in SI-BONE in the third quarter valued at about $48,000. Larson Financial Group LLC purchased a new position in shares of SI-BONE in the first quarter worth about $49,000. Finally, Coppell Advisory Solutions LLC purchased a new position in shares of SI-BONE in the second quarter worth about $50,000.

Analyst Upgrades and Downgrades

SIBN has been the topic of several recent research reports. Cantor Fitzgerald decreased their price objective on SI-BONE from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, November 7th. Needham & Company LLC decreased their price target on SI-BONE from $32.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, November 7th. Truist Financial decreased their price target on SI-BONE from $33.00 to $31.00 and set a “buy” rating on the stock in a report on Tuesday, August 8th. Finally, Morgan Stanley decreased their price target on SI-BONE from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, November 7th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $27.17.

About SI-BONE

SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma.